Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 3Phase 4 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, Non-Hodgkin 2Lymphoma 2Leukemia 2Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, B-Cell 1Bronchiolitis Obliterans Syndrome 1

Interventions

ibrutinib 3Rituximab 3Lenalidomide 3spebrutinib 2fludarabine phosphate 2Cyclophosphamide 2tirabrutinib 1ricolinostat 1pembrolizumab 1ofatumumab 1navitoclax 1idelalisib 1fludarabine 1dinaciclib 1blinatumomab 1Rabeprazole 1Magnetic Resonance Imaging 1MLN 8237 1Leukapheresis 1KW-2478 1Itraconazole 1Immunotherapy, Adoptive 1Electrocardiography 1Echocardiography 1Diphenhydramine 1Ciclopirox 1Blood Component Removal 1Biological Products 1Bendamustine Hydrochloride 1Antiemetics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, B-Cell × ofatumumab × Clear all
NCT01110031 2017-11-13

Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects

GlaxoSmithKline

Phase 1 Completed
12 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡